Biomarkers in Urothelial Cancer Patients Treated With Pembrolizumab

NCT03263039 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

80

Enrollment

OTHER

Sponsor class

Conditions

Transitional Cell Carcinoma of the Bladder
Biomarkers

Interventions

DRUG: Pembrolizumab

Sponsor

Erasmus Medical Center

Collaborators

[object Object]